Current guidelines, recently updated [9] suggest that medical management of CKD-dependent Mineral Bone Disease (CKD-MBD) should be based on serial measurements of serum PTH and also therapeutic decisions should be based on trend rather than on a single laboratory value. This evidence concerns the gene PTH and Marchiafava-Bignami disease.